AR118787A1 - PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES - Google Patents

PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES

Info

Publication number
AR118787A1
AR118787A1 ARP190102387A ARP190102387A AR118787A1 AR 118787 A1 AR118787 A1 AR 118787A1 AR P190102387 A ARP190102387 A AR P190102387A AR P190102387 A ARP190102387 A AR P190102387A AR 118787 A1 AR118787 A1 AR 118787A1
Authority
AR
Argentina
Prior art keywords
binding
binding molecules
molecules
diseases
treatment
Prior art date
Application number
ARP190102387A
Other languages
Spanish (es)
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AR118787A1 publication Critical patent/AR118787A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente está dirigida a moléculas de unión a PD-L1, tales como anticuerpos monoespecíficos, y fragmentos de unión a epítopo de los mismos, que son capaces de unirse a PD-L1, y a moléculas de unión multiespecíficas (por ejemplo, anticuerpos biespecíficos, diacuerpos biespecíficos, BiTEs, moléculas de unión trivalentes, etc.) que son capaces de unirse tanto a un epítopo de PD-L1 como a un epítopo de CD137 (moléculas de unión a PD-L1 ´ CD137). La presente también se dirige a composiciones farmacéuticas que comprenden tales moléculas. La presente también incluye el uso de tales moléculas en el tratamiento de enfermedades, especialmente cáncer o una enfermedad o afección asociada o caracterizada por la presencia de un sistema inmune suprimido.The present invention is directed to PD-L1 binding molecules, such as monospecific antibodies, and epitope-binding fragments thereof, that are capable of binding to PD-L1, and to multispecific binding molecules (eg, bispecific antibodies, bispecific diabodies, BiTEs, trivalent binding molecules, etc.) that are capable of binding both an epitope of PD-L1 and an epitope of CD137 (PD-L1 ´CD137 binding molecules). The present invention is also directed to pharmaceutical compositions comprising such molecules. The present invention also includes the use of such molecules in the treatment of diseases, especially cancer or a disease or condition associated with or characterized by the presence of a suppressed immune system.

ARP190102387A 2018-08-23 2019-08-22 PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES AR118787A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862721984P 2018-08-23 2018-08-23

Publications (1)

Publication Number Publication Date
AR118787A1 true AR118787A1 (en) 2021-11-03

Family

ID=80053327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102387A AR118787A1 (en) 2018-08-23 2019-08-22 PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES

Country Status (1)

Country Link
AR (1) AR118787A1 (en)

Similar Documents

Publication Publication Date Title
CO2018001485A2 (en) Bispecific monovalent diabodies that are capable of binding to b7 - h3 and cd3
CO2018005932A2 (en) Bispecific molecules that have immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CO2018001149A2 (en) Monoclonal antibodies against bcma
ECSP20024555A (en) SPECIFIC ANTIBODIES FOR CD47 AND PD-L1
CO2018010538A2 (en) Specific poliovirus receptor (rvp) antibodies
CO2020008940A2 (en) Gprc5d-binding antibodies
CL2017003195A1 (en) Affinity-matured and humanized antibodies to fcrh5 and methods for their use.
CO2017006740A2 (en) Anti-cd79b antibodies
CU20160101A7 (en) IMMUNOGLOBULINA WITH FAB IN TANDEM
EA201891983A8 (en) COMBINED THERAPY BY ANTIBODIES TO CD73
CL2018001512A1 (en) Humanized anti-CD73 antibodies.
CL2018000744A1 (en) Anti-tigit antibodies (T lymphocyte immunoreceptor with ig and itim domains) and methods of use.
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
CL2016002547A1 (en) Antibodies against bispecific her2
CU24533B1 (en) ANTIBODIES OR FRAGMENTS THEREOF THAT BIND THYMIC STROMAL LYMPHOPOYETIN (TSLP) AND PHARMACEUTICAL COMPOSITIONS THEREOF
PE20171764A1 (en) ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES, AND BISPECIFIC ANTIBODIES THAT SPECIFICALLY BIND CD3 AND / OR CD123
CU24498B1 (en) FACTOR XI ANTIBODIES
EA201791050A1 (en) CONJUGATES OF ANTIBODIES AND MEDICINES
EA201790060A1 (en) BISPECIFIC CD33- and CD3-BINDING PROTEINS
UY35042A (en) ANTI-CD3 ANTIBODIES, BIO-SPECIFIC ANTIGEN MOLECULES THAT JOIN CD3 AND CD20, AND USES OF THE SAME.
BR112016014731A2 (en) ANTI-BAFF ANTIBODIES
UY36942A (en) ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER
CO2018012497A2 (en) Interferon beta antibodies and uses thereof
CO2018001010A2 (en) Monoclonal antibodies specific for the human syncytial respiratory virus (vrsh) antigen, produced and secreted by cellular hybridomas, useful for the detection and diagnosis of infection caused by vrsh
CL2019002735A1 (en) Antibodies that bind to steap-1.

Legal Events

Date Code Title Description
FB Suspension of granting procedure